医薬品リファレンス
Gefitinib
Gefitinib is a medicine in the class oncology. It is used for non-small cell lung cancer.
- 薬効分類: Oncology
- 効能・効果: non-small cell lung cancer
最終更新日 出典: US FDA label
医療従事者向け・参照専用。このページは簡潔な要約であり、医学的助言ではなく、公式の添付文書や臨床判断に代わるものではありません。処方・調剤の前に必ず確認してください。
このページの臨床コンテンツは英語でのみ提供されています。
要点
- 薬効分類
- Oncology
- ATCコード
- L01XE02
- 一般的な剤形
- 錠剤
- 一般的な規格
- 250 mg
- 既知の相互作用
- 39 (重大: 10 · 中等度: 27 · 軽度: 2)
- 商品名
- 3
- 国・市場
- 3
何に使われるか
作用のしくみ
Gefitinib reversibly inhibits the kinase activity of wild-type and certain activating mutations of EGFR, preventing autophosphorylation and blocking downstream signaling and EGFR-dependent proliferation. It binds exon 19 deletion and L858R mutant EGFR with higher affinity than wild-type.
成人の通常用量(添付文書の要約)
First-line metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations: 250 mg orally once daily with or without food until disease progression or unacceptable toxicity
妊娠と授乳
- 妊娠
- Unsafe Can cause fetal harm when given to a pregnant woman; animal studies showed fetotoxicity and neonatal death at doses below the recommended human dose.
- 授乳
- Unsafe It is not known whether excreted in human milk; present in rat milk. Advise women to discontinue breast-feeding during treatment.
報告されている副作用
- Skin reactions
- Diarrhea
- Nail disorders
- Increased ALT
- Increased AST
- Conjunctivitis, blepharitis and dry eye
禁忌
- None.
注意が必要な方
- Interstitial lung disease occurred in 1.3% of patients, with fatal cases. Withhold for worsening respiratory symptoms and discontinue if confirmed.
- Hepatotoxicity: obtain periodic liver function testing; withhold for worsening liver function; discontinue for severe hepatic impairment.
- Gastrointestinal perforation occurred in 0.1% of patients; discontinue permanently.
妊娠中または授乳中であること、腎臓や肝臓の病気、アレルギー、ほかに使用しているすべての薬やサプリメントについて、薬剤師または医師にお伝えください。
主な相互作用 (39)
- Apalutamide + Gefitinib Major
- Carbamazepine + Gefitinib Major
- Dexlansoprazole + Gefitinib Major
- Esomeprazole + Gefitinib Major
- Gefitinib + Lansoprazole Major
- Gefitinib + Omeprazole Major
- Gefitinib + Pantoprazole Major
- Gefitinib + Phenytoin Major
- Gefitinib + Rabeprazole Major
- Gefitinib + Rifampicin Major
Pro+会員向け
ページ全体を見る
アカウントを作成してPro+トライアルを始めると、Gefitinibの完全なモノグラフ(用量、妊娠・授乳、副作用、警告、すべての相互作用)を表示できます。
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Dosing in older adults
- How to give it
- Pharmacokinetics
- Patient counselling points
- Food interactions
WebでPro+を14日間無料でお試し。カード登録不要。
同じ分類のほかの薬剤
よくある質問
What is Gefitinib used for?
Gefitinib is a medicine in the class oncology. It is used for Non-small cell lung cancer.
What side effects have been reported with Gefitinib?
Skin reactions, Diarrhea, Nail disorders, Increased ALT, Increased AST, Conjunctivitis, blepharitis and dry eye.
Can Gefitinib be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause fetal harm when given to a pregnant woman; animal studies showed fetotoxicity and neonatal death at doses below the recommended human dose. Breastfeeding: Unsafe. It is not known whether excreted in human milk; present in rat milk. Advise women to discontinue breast-feeding during treatment.
What does Gefitinib interact with?
MediHelp lists 39 known interactions for Gefitinib. Major: 10 · Moderate: 27 · Minor: 2. The most serious include Apalutamide, Carbamazepine, Dexlansoprazole.
完全なモノグラフ、用量、相互作用チェッカーはMediHelpアプリで
MediHelpアプリで、完全なリファレンスを開き、複数薬剤の相互作用をチェックし、用量ツールを利用できます。